Abstract
Real-world treatment patterns of hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer
- Department of Oncology, Institute of Medical Sciences, University of Opole, Opole, Poland
- Department of Clinical Oncology, Tadeusz Koszarowski Cancer Center, Opole, Poland
- Department of Outpatient Chemotherapy, Professor Franciszek Łukaszczyk Oncology Center, Bydgoszcz, Poland
- Division of Solid Tumour Systemic Therapy, Department of Oncology, Faculty of Medicine, Wrocław Medical University, Wrocław, Poland
- Department of Clinical Oncology, Brest Cancer, Lower Silesion Oncology, Pulmunology and Hematology Centre, Wrocław, Poland
- Department of Clinical Oncology, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków Branch, Kraków, Poland
- Pfizer Polska sp. z o. o., Warszawa, Poland
- Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
- Breast Unit, University Clinical Center, Gdańsk, Poland
Introduction
The HABER study aimed to evaluate real-world treatment patterns for hormone receptor-positive, HER-2-negative (HR+/HER-2–) advanced breast cancer (ABC) in Poland, focusing on adherence to local and international guidelines.
Material and methods
This retrospective, non-interventional analysis included 440 patients treated between September 2020 and August 2021 across 17 clinical sites. The trial was registered with ClinicalTrials.gov, NCT05478590.
Results
Most patients were postmenopausal (76.7%) with a mean age of 62.7 years, and nearly two-thirds had comorbidities. Almost half of the patients (48.6%) were diagnosed with de novo ABC. CDK4/6 inhibitor-based therapies were the predominant first-line treatment (74.1%), aligning with guideline recommendations. These therapies were more frequently combined with aromatase inhibitors (64.7%) than with fulvestrant (35.3%). The mean age ± standard deviation of patients treated with endocrine therapy (71.8 ±11.6 years) was higher than the age at which they received CDK4/6 inhibitors with endocrine therapy (61.3 ±11.7 years) or chemotherapy (62.0 ±13.2 years), p < 0.0001. Patients treated with CDK4/6 inhibitor-based therapy had more often the Eastern Cooperative Oncology Group performance status of 0–1 (90.8%) than those receiving endocrine therapy (48.1%) or chemotherapy (56.7%). Chemotherapy was used primarily for rapid disease progression or life-threatening visceral crises. CDK4/6 inhibitors remained the preferred treatment across all metastatic sites.
Conclusions
Treatment choice was influenced by patient demographics, performance status, and time from early breast cancer to relapse. The observed treatment patterns of first-line treatment of HR+/HER– ABC are highly aligned with current national and international guidelines.
Keywords
Poland, advanced breast cancer, CDK4/6 inhibitors
Coverage in
Indexed in
Integrated with
